Insulet Corporation $PODD Stock Sold by Candriam S.C.A.

Candriam S.C.A. trimmed its holdings in Insulet Corporation (NASDAQ:PODD) by 95.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,416 shares of the medical instruments supplier’s stock after selling 143,684 shares during the quarter. Candriam S.C.A.’s holdings in Insulet were worth $971,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. State of Wyoming lifted its stake in shares of Insulet by 34.6% during the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock worth $60,000 after acquiring an additional 73 shares during the last quarter. Basecamp Wealth Advisors LLC lifted its holdings in Insulet by 48.3% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier’s stock valued at $66,000 after buying an additional 102 shares in the last quarter. Elevation Wealth Partners LLC boosted its position in Insulet by 115.6% in the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 104 shares during the period. Pinnacle Associates Ltd. boosted its position in Insulet by 6.1% in the 3rd quarter. Pinnacle Associates Ltd. now owns 1,855 shares of the medical instruments supplier’s stock valued at $242,000 after buying an additional 107 shares during the period. Finally, NorthCrest Asset Manangement LLC grew its stake in Insulet by 4.4% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 3,194 shares of the medical instruments supplier’s stock worth $429,000 after acquiring an additional 134 shares in the last quarter.

Analysts Set New Price Targets

PODD has been the topic of a number of research reports. UBS Group raised their target price on shares of Insulet from $150.00 to $171.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. Wells Fargo & Company boosted their price target on Insulet from $144.00 to $172.00 and gave the company an “equal weight” rating in a report on Thursday, November 5th. Canaccord Genuity Group dropped their price objective on Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Leerink Partners increased their price objective on Insulet from $143.00 to $167.00 and gave the stock a “market perform” rating in a research note on Thursday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Insulet in a research report on Monday, September 21st. Twelve research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $185.67.

Insulet Stock Up 1.3%

Insulet stock opened at $150.03 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.51 and a quick ratio of 1.83. The stock has a market capitalization of $10.41 billion, a price-to-earnings ratio of 24.43, a PEG ratio of 1.13 and a beta of 1.06. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88. The business has a fifty day moving average price of $142.08 and a 200-day moving average price of $174.71.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The business had revenue of $842.00 million for the quarter, compared to analyst estimates of $832.63 million. During the same quarter in the previous year, the firm earned $1.24 earnings per share. The company’s revenue was up 19.2% on a year-over-year basis. Equities research analysts forecast that Insulet Corporation will post 6.75 EPS for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.